Ford 6000 Cd Code Serial Vital

Adobe Flash Player is required to view this feature. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Original Article Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia James Shepherd, M.D., Stuart M. Cobbe, M.D., Ian Ford, Ph.D., Christopher G. Isles, M.D., A.

Request a Crack or Dongle Emulator Dongle Crack for any.

Ross Lorimer, M.D., Peter W. Macfarlane, Ph.D., James H. McKillop, M.D., and Christopher J. Packard, D.Sc., for the West of Scotland Coronary Prevention Study Group N Engl J Med 1995; 333:1301-1308 DOI: 10.1056/NEJM32001. Results Pravastatin lowered plasma cholesterol levels by 20 percent and low-density lipoprotein cholesterol levels by 26 percent, whereas there was no change with placebo. There were 248 definite coronary events (specified as nonfatal myocardial infarction or death from coronary heart disease) in the placebo group, and 174 in the pravastatin group (relative reduction in risk with pravastatin, 31 percent; 95 percent confidence interval, 17 to 43 percent; P. Earlier trials of lipid-lowering drugs in the primary prevention of coronary heart disease have demonstrated that lowering cholesterol levels in middle-aged men with hypercholesterolemia reduces the incidence of myocardial infarction.

However, these studies, because of their design and low rates of observed events, were unable to show a clear effect of therapy on the risk of death from coronary heart disease or death from any cause. A meta-analysis of the trials provided support for the likelihood that therapy lowered the risk of death from coronary heart disease, but it also aroused concern that the risk of death from noncardiovascular causes might be increased by treatment. Whether this latter association was due to chance, to the reduction in cholesterol itself, or to an adverse effect of the drugs is not clear. Recently, a new class of lipid-lowering drug, the 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitors, has been introduced into clinical practice.

These drugs block endogenous synthesis of cholesterol and reduce the levels of low-density lipoprotein (LDL) cholesterol. They slow the progression of coronary disease and reduce the incidence of death from coronary causes and death from any cause in men with manifest coronary heart disease. The present study was designed to evaluate the effectiveness of a reductase inhibitor, pravastatin (Pravachol), in preventing coronary events in men with moderate hypercholesterolemia and no history of myocardial infarction. Design The objective was to enroll approximately 6000 middle-aged men, randomly assigned in a double-blind fashion to receive either pravastatin (40 mg each evening) or placebo and to record their clinical progress over a period of five years.

The details of the study design, including the definitions of the end points, have been described previously. Briefly, the primary end point of the study was the occurrence of nonfatal myocardial infarction or death from coronary heart disease as a first event; these two categories were combined. Other principal end points were the occurrence of death from coronary heart disease and nonfatal myocardial infarction. In all categories, the events were classified as either definite or suspected.

In addition to the main end points, the effect of treatment on death from cardiovascular causes, death from any cause, and the frequency of coronary revascularization procedures was analyzed. All subjects provided written informed consent. The study was approved by the ethics committees of the University of Glasgow and all participating health boards.

Recruitment and Follow-up Coronary screening clinics were established in primary medical care facilities throughout the West of Scotland district. Approximately 160,000 men ranging in age from 45 to 64 years were invited to attend the clinics to assess their coronary risk factors. A total of 81,161 appeared for the first visit, and those whose nonfasting plasma cholesterol level was at least 252 mg per deciliter (6.5 mmol per liter) but who had no history of myocardial infarction were given lipid-lowering dietary advice and asked to return four weeks later. A total of 20,914 men returned for the second visit, at which time a lipoprotein profile was obtained that measured plasma cholesterol, the cholesterol content of LDL and high-density lipoprotein (HDL), and plasma triglycerides while the subjects were fasting. If on this occasion the LDL cholesterol level was at least 155 mg per deciliter (4.0 mmol per liter) and the subject had no exclusion criteria, he was advised to stay on the lipid-lowering diet for a further four weeks and then to return for a third visit (13,654 attended), at which time a second lipoprotein profile and a 12-lead electrocardiogram (ECG) were obtained.

Laboratory Analyses The cholesterol measurement during the first visit was performed on a Reflotron bench-top analyzer (Boehringer–Mannheim, Lewes, Kent, United Kingdom). All subsequent laboratory analyses, including biochemical, hematologic, and lipoprotein profiles, were conducted at the central laboratory at the Glasgow Royal Infirmary. Lipoprotein profiles were determined according to the Lipid Research Clinics protocol with enzymatic cholesterol and triglyceride assays. The laboratory was certified through the Lipid Standardization Program of the Centers for Disease Control and Prevention in Atlanta. Abnormalities in the results of blood tests were identified with the use of published reference ranges.

Siemens Sicard 440 electrocardiographs were used to record the 12-lead ECGs, and the data were transmitted by telephone to the ECG core laboratory at the Glasgow Royal Infirmary for storage on a central Mingocare data base (Siemens Elema, Stockholm, Sweden) and subsequent automated classification according to the Minnesota code, including serial comparisons. All ECG results were verified by visual inspection. Identification and Classification of End Points At each follow-up visit, adverse events were documented on the basis of the subjects' recall, and if appropriate, further information was obtained from hospital records. All data on randomized subjects were flagged electronically on national computer data bases so that the numbers of deaths, incident cancers, hospitalizations, and cardiac surgeries could be monitored according to previously described methods. Potential end points were reviewed and classified according to predefined criteria by the End-Points Committee, whereas non–coronary heart disease events were reviewed and classified by the Adverse-Events Committee.

Free Download Anggun C Sasmi Berganti Hati on this page. The progress and conduct of the study were monitored regularly by the independent, unblinded Data and Safety Monitoring Committee. Except for the trial statistician and his assistant, all trial personnel remained unaware of the subjects' treatment assignments throughout the study.

Statistical Analysis All data were analyzed according to the intention-to-treat principle. The results of the two fasting lipoprotein profiles obtained during visits 2 and 3 were averaged to produce base-line values. The LDL cholesterol results were analyzed according to both the treatment actually received and the intention-to-treat principle. The analysis based on actual treatment used only the measured lipid levels in subjects who had attended the previous scheduled visit and who had been issued with trial medication at that visit. For the intention-to-treat analysis, all recorded levels were included, without reference to the subjects' degree of compliance at previous visits. In addition, in cases in which no lipid value was available for a scheduled visit and no medication had been issued at the previous visit, the subject's base-line level was used.

For each end-point category, the lengths of time to a first event were compared with use of the log-rank test, and the relative reduction in risk resulting from pravastatin treatment, with 95 percent confidence intervals, was calculated with the Cox proportional-hazards model. In addition, Kaplan–Meier time-to-event curves were used to estimate the absolute risk of each event at five years for each treatment group. When a silent myocardial infarction was detected on the basis of serial comparison of ECGs, the event was considered to have occurred midway between the first diagnostic ECG and the previous ECG. Two-tailed P values were used throughout. For the primary end point, an analysis was performed for predefined subgroups characterized at base line according to age (55 years), smoking status (smoker or nonsmoker of cigarettes, cigars, or pipes), and whether at least two of the following risk factors were present: smoking, hypertension, a history of chest pain or intermittent claudication (as indicated by positive responses on the Rose questionnaire), diabetes, and a minor ECG abnormality associated with coronary heart disease (Minnesota code 4-2, 4-3, 5-2, or 5-3).

In addition, the effect of treatment was examined in a subgroup with and a subgroup without vascular disease at base line. Vascular disease was considered to be present if there was evidence of angina, intermittent claudication, stroke, transient ischemic attack, and ECG abnormalities according to the Minnesota code. Finally, the influence of base-line lipid levels on the effect of treatment was assessed by dividing the randomized population according to the median plasma cholesterol, LDL or HDL cholesterol, or plasma triglyceride concentration. The Data and Safety Monitoring Committee conducted annual reviews of the main end points according to the O'Brien and Fleming criteria for stopping the trial prematurely. The overall P value indicating statistical significance was set at 0.01. Results A total of 6595 subjects underwent randomization.

The clinical characteristics of the subjects who were screened and those who were randomized have been described previously. The first patient was enrolled on February 1, 1989, and recruitment was completed by September 30, 1991.

The final visits were made between February and May 1995, by which time the study population had accrued 32,216 subject-years of follow-up (an average of 4.9 years per subject). At the end of the study, the vital and clinical status of all randomized subjects was ascertained. The base-line characteristics of the pravastatin and placebo groups are summarized in Table 1 Base-Line Characteristics of the Randomized Subjects, According to Treatment Group..

As expected in a trial of this size, the groups were well balanced. For the study population as a whole, the average (±SD) plasma cholesterol level was 272±23 mg per deciliter (7.0±0.6 mmol per liter), the LDL cholesterol level was 192±17 mg per deciliter (5.0±0.5 mmol per liter), and the HDL cholesterol level was 44±9 mg per deciliter (1.14±0.26 mmol per liter). On the basis of positive responses on the Rose questionnaire, evidence of angina was present in 5 percent of the men, whereas 8 percent had ECG ST-T wave changes (Minnesota codes 4-2, 4-3, 5-2, and 5-3).

The prevalence of self-reported diabetes mellitus was 1 percent, and that of hypertension was 16 percent; 44 percent of the subjects were current smokers. Withdrawals The cumulative rates of withdrawal from treatment in the placebo and pravastatin groups were 14.9 percent and 15.5 percent, respectively, at year 1, 19.1 percent and 19.4 percent at year 2, 22.5 percent and 22.7 percent at year 3, 25.2 percent and 24.7 percent at year 4, and 30.8 percent and 29.6 percent at year 5. There was no significant difference in the withdrawal rates between the two groups at any time. The disproportionate increase from year 4 to year 5 can be attributed to the withdrawal from the study of some subjects who had completed the five years of follow-up and who could have proceeded further but did not wish to do so. Reduction in Lipid Levels When the data were analyzed according to the treatment actually received, pravastatin was found to have lowered plasma levels of cholesterol by 20 percent, LDL cholesterol by 26 percent ( Figure 1 Effects of Pravastatin Therapy on Plasma LDL Cholesterol Levels.

To convert values for cholesterol to millimoles per liter, multiply by 0.026. ), and triglycerides by 12 percent, whereas HDL cholesterol was increased by 5 percent. There were no such changes with placebo. When the data were analyzed according to the intention-to-treat principle, because such analysis includes subjects who withdrew and noncompliant subjects, there was an apparent reduction in the observed difference in LDL cholesterol levels between treatment groups over time. This result is in contrast to that based on actual treatment, which showed that the differnce was maintained. End Points As compared with placebo, pravastatin produced a significant reduction in the risk of the combined primary end point of definite nonfatal myocardial infarction and death from coronary heart disease (reduction, 31 percent; 95 percent confidence interval, 17 to 43 percent; P.

Other Adverse Events In the pravastatin group 116 subjects had incident (fatal or nonfatal) cancers, as compared with 106 in the placebo group (P = 0.55). These figures include cases of malignant melanoma but not minor skin cancers. For the placebo and pravastatin groups, respectively, there were 30 and 31 gastrointestinal cancers, 26 and 32 genitourinary cancers, 28 and 27 respiratory tract cancers, and 22 and 26 other cancers.

Twenty subjects in the pravastatin group reported myalgia, and 97 muscle aches. The corresponding numbers in the placebo group were 19 and 102 (P not significant). Four subjects (three in the pravastatin group and one in the placebo group) had asymptomatic episodes of elevated creatine kinase concentrations (>10 times the upper reference limit). Elevations in aspartate aminotransferase and alanine aminotransferase values (>3 times the upper reference limits) were recorded for 26 and 16 subjects, respectively, in the pravastatin group, as compared with 20 and 12 subjects in the placebo group (P not significant). Discussion As compared with placebo, pravastatin reduced the risk of fatal or nonfatal coronary events in middle-aged men with hypercholesterolemia and no history of myocardial infarction by approximately 30 percent. The beneficial effects of treatment were remarkably consistent across a variety of coronary end points.

In contrast to the results of studies using resins, fibrates, or other 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitors, the time-to-event curves began to diverge within six months of the initiation of treatment and continued to do so at the same rate throughout the trial. The frequency of the need for coronary angiography and revascularization procedures was significantly lower in the pravastatin group than in the placebo group. The subjects in this study were representative of the general population in terms of socioeconomic status and risk factors ( ). Their plasma cholesterol levels were in the highest quartile of the range found in the British population.

A number had evidence of minor vascular disease, and in order to make the findings of the trial applicable to typical middle-aged men with hypercholesterolemia, they were not excluded. In line with accepted guidelines, the LDL cholesterol level was used as a criterion for entry into the study.

As compared with placebo, pravastatin produced a major reduction in this lipoprotein fraction ( ) and moderate decreases in plasma triglycerides, as well as an increase in HDL cholesterol. These changes are in line with the expected response to pravastatin, and all could potentially result in clinical benefit. The changes in the LDL cholesterol level are more substantial than those observed in earlier primary prevention studies. When the subjects were divided into two groups according to their lipid levels at base line, we found that coronary risk was related to higher plasma LDL cholesterol and triglyceride levels (i.e., levels above the median values) and lower HDL cholesterol levels (i.e., levels below the median value) ( ).

The plasma cholesterol level was not a significant factor, principally because of the narrow range of cholesterol values used as a criterion for entry into the study. The relative reduction in risk with pravastatin therapy was statistically significant and of a similar magnitude in subjects with lipid values above and below the median. The relative reductions in risk attributable to pravastatin therapy were not affected by age (55 years) or smoking status. Furthermore, a significant treatment effect was seen in the subgroup without multiple risk factors and the subgroup without preexisting vascular disease. Thus, it is possible to conclude that in the subjects who might be considered to fall strictly into the primary-prevention category, pravastatin therapy produced a significant reduction in the relative risk of a coronary event. Pravastatin therapy was well tolerated and resulted in no more study withdrawals than placebo. In particular, as in an earlier study, there was no evidence that pravastatin adversely affected liver function or caused myopathy.

Our results support those of a recent secondary-prevention trial that found that lipid lowering with a 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitor is not associated with an increased risk of death from noncardiovascular causes. As in that earlier trial, a comparison of the treatment and placebo groups showed no significant increase in the incidence of fatal or incident cancers or deaths due to suicide or trauma. More data on the adverse-event profile of this class of drugs will become available as the results of other prevention trials are published.

In the current study, the benefit of pravastatin therapy with respect to fatal coronary events and the absence of any increase in the number of deaths from other causes led to a 22 percent reduction in the relative risk of death from any cause (P = 0.051). From the data in, it can be estimated that treating 1000 middle-aged men with hypercholesterolemia and no evidence of a previous myocardial infarction with pravastatin for five years will result in 14 fewer coronary angiograms, 8 fewer revascularization procedures, 20 fewer nonfatal myocardial infarctions, 7 fewer deaths from cardiovascular causes, and 2 fewer deaths from other causes than would be expected in the absence of treatment. Since these figures are based on an intention-to-treat analysis, the magnitude of the benefit in fully compliant subjects is likely to be greater. These findings can be compared favorably with the results of the Medical Research Council trial of the treatment of mild hypertension in middle-aged subjects. In that study, it was estimated that five years of active treatment of 1000 men ranging in age from 35 to 64 years would result in six fewer strokes and two fewer cardiovascular events than would be expected. Thus, our results indicate that reducing cholesterol levels with pravastatin reduces the risk of coronary events in asymptomatic subjects with hypercholesterolemia. Futaba Pulscale Manual.

Source Information From the Departments of Pathological Biochemistry (J.S., C.J.P.), Medical Cardiology (S.M.C., A.R.L., P.W.M.), and Medicine (J.H.M.), University of Glasgow and Royal Infirmary, Glasgow; Robertson Centre for Biostatistics, University of Glasgow, Glasgow (I.F.); and the Department of Medicine, Dumfries and Galloway District General Hospital, Dumfries (C.G.I.) — all in Scotland. Address reprint requests to Dr. Ford at the Robertson Centre for Biostatistics, Boyd Orr Bldg., University of Glasgow, Glasgow G12 8QQ, Scotland. Appendix The members of the West of Scotland Coronary Prevention Study are as follows: Executive Committee (Voting Members) — J.

Shepherd (chairman), S.M. Lorimer, J.H. Packard, P.W. Macfarlane, and G.C. Isles; Data and Safety Monitoring Committee — M.F. Oliver (chairman), A.F. Brown, J.G.G.

Ledingham, S.J. Pocock, and B.M. Rifkind; End-Points Committee — S.M. Vallance, P.W. Macfarlane; Adverse-Events Committee — A.R. Lorimer, J.H.

McKillop, and D. Ballantyne; Data-Center Staff — L. Montgomery, and J. Norrie; Population Screening — M. Percy; Clinical Coordination, Monitoring, and Administration — E. Whitehouse, P.

Fletcher, and C. Kilday; Computerized ECG Analysis — D.

Shoat (deceased), S. Latif, and J. Kennedy; Laboratory Operations — M.A. Birrell; and Company Liaison and General Support — M. Meyer, and W.

References • 1 A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate: report from the Committee of Principal Investigators. Br Heart J 19-1118 • 2 The Lipid Research Clinics Coronary Primary Prevention Trial results.

Reduction in incidence of coronary heart disease. JAMA 1984;251:351-364 • 3 The Lipid Research Clinics Coronary Primary Prevention Trial results. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering.

JAMA 1984;251:365-374 • 4 Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245 • 5 Oliver MF.

Might treatment of hypercholesterolaemia increase non-cardiac mortality? Lancet 1991;337:1529-1531 • 6 Hulley SB, Walsh JMB, Newman TB. Health policy on blood cholesterol: time to change directions.

Circulation 19-1029 • 7 Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 1992;304:431-434 • 8 LaRosa JC, Hunninghake D, Bush D, et al. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease: a joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute.

Circulation 19-1733 • 9 The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389 • 10 MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-638[Erratum, Lancet 1994;344:762.] • 11 Furberg CD, Adams HP Jr, Applegate WB, et al.

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 19-1687 • 12 Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS).

Circulation 19-2540 • 13 Crouse JR III, Byington RP, Bond MG, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995;75:455-459[Erratum, Am J Cardiol 1995;75:862.] • 14 Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park J-SP, McGovern ME. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol (in press). • 15 The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors.

Am J Cardiol 19-1037 • 16 West of Scotland Coronary Prevention Study Group. A coronary primary prevention study of Scottish men age 45-64 years: trial design. J Clin Epidemiol 1992;45:849-860 • 17 EAS Task Force for Prevention of Coronary Heart Disease. Prevention of coronary heart disease: scientific background and new clinical guidelines.

Nutr Metab Cardiovasc Dis 1992;2:113-156 • 18 Prineas RJ, Crow RS, Blackburn H. The Minnesota code manual of electrocardiographic findings: standards and procedures for measurement and classification. Boston: John Wright, PSG, 1982. • 19 Lipid Research Clinics manual of laboratory operations, 1975. Washington, D.C.: Government Printing Office, 1975.

(DHEW publication no. (NIH) 85-268.) • 20 Crow RS, Prineas RJ, Jacobs DR Jr, Blackburn H. A new epidemiologic classification system for interim myocardial infarction from serial electrocardiographic changes. Am J Cardiol 1989;64:454-461 • 21 Macfarlane PW, Devine B, Latif S, McLaughlin S, Shoat DB, Watts MP. Methodology of ECG interpretation in the Glasgow program. Methods Inf Med 1990;29:354-361 • 22 Macfarlane PW, Latif S.